Progress and challenges in the manufacturing of CAR-T cell therapy

In by

Spotlight Article


Michelle myers

Latest advances in CAR-T cell manufacturing


Dr Bruce Levine

Dr Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a BA in Biology from the University of Pennsylvania and a PhD in Immunology and Infectious Diseases from the Johns Hopkins University. The CVPF develops and tests novel cell and gene therapies in clinical trials in patients with hematologic malignancies, solid tumors, HIV infection and genetic disease. First-in-human trials include the first use of a lentiviral vector, the first infusions of zinc finger nuclease genome-modified cells, and the first use of lentivirally-modified cells to treat cancer. Dr Levine has overseen the production, testing and release of 2700 cellular products administered to >1000 patients in clinical trials since 1996. Through these technologies, personalized and enhanced immunity has been engineered. T lymphocytes from HIV+ subjects have been rendered resistant to HIV infection and reinfused. T lymphocytes from cancer patients have been redirected with chimeric antigen receptors to hunt and destroy their malignancies, an investigational therapy that received the first Breakthrough Designation from the FDA for an academic institution and is currently in commercial development. Dr Levine is co-inventor on 23 issued US patents and co-author of >125 publications with a Google Scholar citation h-index of 66. He has been interviewed by the NY Times, Wall Street Journal, Forbes, BBC and other international media outlets.

DOI: 10.18609/cgti.2017.027
Citation: Cell Gene Therapy Insights 2017;3(4), 255-260.
Open access

This content is restricted to registered users. Click here to Register or Login here.